Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00422487 · ClinicalTrials.gov registry record · Phase 2
Safety and Tolerability Study of MBX-2044 in Patients With Type 2 Diabetes
A Phase 2 study, sponsored by Gilead Sciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
NCT00422487 is a Phase 2 study that has completed, run by Gilead Sciences. The registered enrollment target is 60 participants.
The verdict
NCT00422487, a Phase 2 study, has completed, sponsored by Gilead Sciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
Study Summary
The purpose of this study is to collect important information regarding the glucose-lowering efficacy of MBX-2044 and the safety of MBX-2044 (especially weight gain and edema) in diabetics. It will also provide important information about the appropriate doses to be used in subsequent longer-term studies to evaluate the safety and efficacy of MBX-2044 alone and in combination with other anti-diabetic agents.
Interventions
- DRUG MBX-2044
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2006-10 |
| Est. Completion | 2007-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00422487
The ClinicalTrials.gov registry entry for NCT00422487 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which MBX-2044 is the first listed.
NCT00422487 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00422487 about?
NCT00422487 is a clinical study titled "Safety and Tolerability Study of MBX-2044 in Patients With Type 2 Diabetes". The purpose of this study is to collect important information regarding the glucose-lowering efficacy of MBX-2044 and the safety of MBX-2044 (especially weight gain and edema) in diabetics. It will also provide important information about the appropriate doses to be used in subsequent longer-term st...
What is the current status of trial NCT00422487?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2006-10. Estimated completion is 2007-09.
What interventions are being tested in trial NCT00422487?
The interventions under investigation include: MBX-2044 (DRUG).
Who is sponsoring clinical trial NCT00422487?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.